KDC-MN-318 – Kodiac biolabs

Plain-language summaryIntrigue 56 / 100

Cabergoline, sold as Dostinex, is a long-acting ergot dopamine agonist with a half-life measured in days rather than hours, allowing once or twice weekly dosing. It is the first-line drug for prolactinomas (pituitary tumors that secrete the hormone prolactin), where it normalizes hormone levels and shrinks tumors in most patients. The principal safety concern is heart valve damage from chronic 5-HT2B receptor activation, which has been documented at high cumulative doses used in Parkinson disease. At the lower doses used for prolactinomas the valve risk appears small but is not zero, and patients on long-term therapy receive periodic echocardiograms. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

48/100

Gold-standard prolactinoma agent with settled mechanism and limited frontier research appeal

Look, cabergoline is one of those compounds where the clinical story is essentially settled and the research frontier has moved on. FDA approved in 1996, it displaced bromocriptine as the first-line agent for hyperprolactinemia and prolactinoma on every metric that matters: efficacy, tolerability, dosing convenience from that 60-to-100-hour half-life, and a cleaner receptor selectivity profile. Within its approved indication, cabergoline is about as clear a category winner as you’ll find in endocrinology. Thats where the differentiation score comes from.

The problem, from a research library standpoint, is that the interesting questions have already been answered. D2 receptor agonism is thoroughly understood pharmacology. The prolactin-lowering mechanism is textbook. The 5-HT2B partial agonism and its valvulopathy risk at Parkinson-range cumulative doses is documented, quantified, and clinically contextualized. There is no mechanistic mystery here, no new receptor biology to untangle, no signal that tells a serious investigator something genuinely new is waiting.

The off-label angles that occasionally surface — cocaine dependence, reward-circuit modulation, sexual function — have been explored in small studies for years without producing compelling, replicated human signal. We think the cocaine dependence rationale is actually sound: D2 receptor downregulation is a real feature of stimulant use disorder, and restoring D2 tone with a clean long-acting agonist is a plausible pharmacological intervention. But the clinical trial record has been modest and inconsistent across groups, and that keeps the translational score honest even for that angle.

What we genuinely like about cabergoline for bench work is its utility as the canonical long-acting D2 reference agonist. If your research program touches dopamine receptor dynamics, prolactin as a neuroendocrine readout, or D2-mediated feedback loops in reward or reproductive biology, cabergoline is a clean, well-characterized probe. Oral bioavailability is solid, half-life is predictable, and D2 selectivity over non-dopaminergic receptors is meaningfully better than bromocriptine. For those specific programs, it earns its place on the shelf.

Honestly, thats about as far as the excitement goes. Cabergoline has been used clinically for three decades and the evidence base reflects that maturity — but maturity cuts both ways. Well-replicated findings in a settled indication don’t move the frontier. For labs working directly on prolactin biology or D2 receptor pharmacology, it’s a genuinely valuable reference tool. For most other research programs, the literature is closed and there isn’t much discovery space left.

Novelty: 22
Mechanism promise: 30
In-category differentiation: 58
Evidence quality: 68
Translational signal: 72
Research bench value: 48

Rationale Cabergoline scores high on differentiation and translational signal because it is definitively best-in-class for its approved indication, but novelty and mechanism scores drag the overall down hard — it’s a 30-year-old single-receptor ergoline with no meaningful mechanistic surprises and a research conversation that’s largely closed. The off-label angles (cocaine dependence, reward modulation) have produced modest, inconsistent human data that don’t rescue the novelty picture.

Long-acting ergoline D2 dopamine agonist

A long-acting ergoline D2 dopamine receptor agonist; first-line for prolactinoma and used off-label for Parkinson disease maintenance.

Abstract

Cabergoline ((6aR,9R,10aS)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-7-(2-propenyl)-ergoline-8-beta-carboxamide; CAS 81409-90-7; molecular formula C26H37N5O2; molecular weight 451.61) is a long-acting ergoline D2 dopamine receptor agonist developed at Pharmacia and approved by the FDA in 1996 under the trade name Dostinex. The compound has high D2 affinity (Ki approximately 0.6 nM) with minimal activity at non-dopaminergic receptors compared to bromocriptine. Plasma half-life is approximately 60 to 100 hours, the longest of any clinical dopamine agonist, supporting twice-weekly oral dosing. Approved for hyperprolactinemia (prolactinoma, idiopathic hyperprolactinemia). Off-label use in Parkinson disease (less common since the introduction of non-ergot agonists), cocaine dependence, and dopamine-deficiency syndromes. The 5-HT2B partial agonism produces a recognized but rare risk of cardiac valvulopathy at high cumulative doses (Parkinson dose ranges); the lower prolactinoma doses are not associated with this risk. Used as the canonical long-acting ergoline dopamine agonist.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-318Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-318

Cabergoline

Abstract

Read the full monograph